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received an added benefit, in France all drugs assessed received a positive SMR 
and no improvement in actual benefit.
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Objectives: To evaluate the prevalence and patterns of CAM use among dia-
betes patients in Pakistan. In addition, the study also focused on the perceived 
effectiveness of CAM over conventional therapies, information seeking behavior 
and CAM disclosure to healthcare providers. MethOds: A prospective, cross-
sectional and self-administered questionnaire based study was conducted in 
tertiary care public hospitals in Pakistan. A prevalence based sample of 350 dia-
betes patients attending the tertiary hospital in Punjab, Pakistan were selected 
for the study. All obtained data were analyzed using descriptive and inferential 
statistics. Results: Overall, 327 questionnaires were completed and included in 
the analysis, showing that 52.8% of diabetics had used CAM, with most (62.4%) 
believing that CAM therapies assist body’s natural forces to heal. CAM usage 
was significantly associated with gender (P= 0.001), level of education (P= 0.001), 
employment status (P= 0.03) and monthly income (P< 0.001). cOnclusiOns: 
Diabetes treatment and management requires compliance to effective therapies 
at early stages. Healthcare providers should engage diabetics in an open non-judg-
mental dialogue to ascertain better understanding of diabetes and its management 
options.
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Objectives: Since 2011, an early benefit assessment is required for all new drugs 
being launched in Germany. Evidence submitted by pharmaceutical companies 
in dossiers is assessed by the Institute for Quality and Efficiency in Health Care 
(IQWiG) and subsequently appraised by the German Federal Joint Committee (FJC). 
The exact determination of the patient target population plays an important role 
for subsequent price negotiations. In diabetes mellitus type 2 the size of target 
population varies considerably between dossiers. Our aim was to explore the 
reasons for these differences. MethOds: We analyzed 20 dossiers with drugs for 
diabetes mellitus type 2 published between January 2012 and May 2015. Details 
regarding the estimation of the target population were extracted and compared. 
Based on the extractions a criteria list was developed to categorize possible rea-
sons for different sizes of the target population. Results: The estimations of the 
target population were mainly based on secondary data analyses of drug prescrip-
tions. The methods and assumptions used to analyze these data varied widely. 
Important reasons for differences in the estimations are the kind of database, the 
time frame, the operationalization of diabetes patients, the specification of the 
target population, the type of contraindications, the consideration of currently 
undetected patients, the mode of extrapolation to the overall population, and the 
portion of statutory health insurance patients. We could not identify one reason 
that could explain most of the deviations in the size of the target population. 
Several reasons seem to interact and it was not possible to determine the direc-
tion or size of the effect. cOnclusiOns: There is a strong need for more detailed 
descriptions of the methods and databases used in the dossiers to estimate the 
size of the target populations. A harmonization of the methods seems to be help-
ful to reduce the variation.
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Objectives: Modifiable risk factors such as trio Hs are major contributor to the 
disease burden in Malaysia. Heart disease is number one leading cause of death 
in the country and individuals with diabetes are two to four times more likely 
to develop heart disease or stroke relative to those without diabetes. In view of 
severe multifold outcome caused by trio Hs, we aim to examine the prevalence of 
undiagnosed trio Hs and management of these risk factors among participants 
who had previously detected with these conditions. MethOds: We retrospec-
tively performed secondary data analysis on random selective samples from 
Pfizer Care-a-Van community health screening which was established in year 
1999. Health screenings were conducted in mobile examination centers across 
the country by a team of registered physician, nurses, and volunteers along with 
various NGO partners. Standardized screening forms were used to collect demo-
graphic data and screening results. Participants with abnormal screening results 
will be referred to government clinics or hospitals for further tests and/or treat-
ment. Descriptive analysis was performed using Stata 13. Results: A total of 
7601 subjects were available for analysis from 2003 till 2014. Over half (58.4%) of 
the screening participants were female aged 45.8 years (SD, 14.4). 13.3% had been 
previously diagnosed with hyperlipidemia, while 10.6% and 13.1% were diabetic 
and hypertensive. Undiagnosed hyperlipidemia was reported at 56.5%, followed 
by hyperglycemia (32.5%) and hypertension (17.8%). Almost half (49.9%) of hyper-
tensive and 59.2% hyperlipidemia subjects failed to achieve target blood pres-
sure and cholesterol level whereas only 38.2% diabetic had their blood glucose 
under control. cOnclusiOns: Multiple risk factors pose a significant burden 
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Objectives: The aim of this study was to assess the burden of peripheral arte-
riopathy (PA) in diabetic patients. MethOds: Eligible patients were identified 
through a data warehouse (DENALI), which matches clinical and economic data 
of about 9.9 million individuals of Lombardy, a northern Italian region which 
represent 16.4% of the Italian population. The study population was made of all 
individuals over 40 with a diagnosis of diabetes who during the period 1-1-2002 
to 31-12-2009 had an hospital admission (index event) attributable to PA disease. 
The identified individuals were followed-up from the index event to a maximum 
of 7 years. We evaluated demographic characteristics of the study population 
and costs (hospitalizations, drugs and outpatient examinations/visits) from the 
National Health Service’s perspective. Results: During the observational period 
18,344 subjects (5% of the diabetic source population) had at least one hospital 
admission of interest. Median age (min-max) at the index date was 73(40-102) 
and 31% of the study population had a Charlson comorbidity index higher than 3. 
The overall mortality was 11.3 deaths every 100 patient-years (95%C.I., 11.1-11.6). 
Forty-four percent of the study population had at least one procedure among 
vascularization, minor and major amputation. Mean cost and corresponding 95% 
C.I. (€ /patient-year) for PA diabetic patients was 14,085(12,344-16,400) in the index 
year and around 7,000 in the following periods of observation. Hospitalizations 
represented the driver of total costs. cOnclusiOns: This study attempted to 
describe the epidemiologic and economic burden of diabetes patients with PA 
complications, showing the relevance of related epidemiologic and economic 
aspects.
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Objectives: Dipeptidyl peptidase-4 (DPP-4) inhibitors were recently approved 
in the US. The objective is to evaluate the prescribing behavior of traditionally 
used type 2 diabetic medications and the newer DPP-4 inhibitors. MethOds: 
This cross-sectional study used data from the 2006-2010 National Ambulatory 
Medical Care Survey (NAMCS) and employed the Eisenberg model of physi-
cian decision making. The dependent variable was the use of DPP-4 inhibitors. 
The following independent variables were determined based on the Eisenberg 
model: age, gender, race/ethnicity, insurance type, primary care physician, 
practice region, metropolitan status, practice setting, previous physician office 
visits, and the type of diabetes medication, and survey year. Multivariate logis-
tic regressions were used for analyses. Results: The estimated population 
size was 535,158,796 patients with type 2 diabetes, and 3.85% of them were 
prescribed DPP-4 inhibitors. The most frequently used diabetic medication 
group was biguanides (metformin) (26.1%), followed by sulfonylurea (17.8%). 
The use of other diabetes medication was highly associated with the likelihood 
of the use of DPP-4 inhibitors. Patients who were prescribed sulfonylurea were 
approximately twice and patients who were prescribed biguanides (metformin) 
were approximately three times more likely to be prescribed DPP-4 inhibitors 
(OR = 1.62; p = 0.009 and OR = 2.96; p < 0.001, respectively). The likelihood of 
the use of DPP-4 inhibitors was also increased with patients receiving insulin 
(OR = 1.62; p = 0.009). cOnclusiOns: The prescribing of the DPP-4 inhibi-
tors increased with current use of biguanides (metformin), sulfonylureas, and 
insulin.
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Objectives: In recent years new type II diabetes (T2D) therapies were launched 
and evaluated by the different market access authorities in France and Germany. 
Decisions were mostly controverse especially in Germany why a comparison 
with comparable health care systems is required. The international Prismaccess 
database includes all evaluations and decisions in France and Germany, besides 
other global authorities. MethOds: All decisions for new T2D therapies in 2014 
and 2015 which were evaluated by the authorities in France and Germany were 
systematically searched for. A comparison was executed with a focus on reim-
bursement decision, basis of decision, acceptance of submitted clinical endpoints, 
study designs, and comparators. Results: In total there were 9 new therapies 
evaluated in France by the Transparency Commission. The level of added benefit 
differed mainly dependent on the combination or monotherapy analyses with 
other OADs and/or insulin. Five out of 9 drugs had all anti-diabetic drugs as com-
parators without specific distinction and 8 out of 9 drugs were rated with an ASMR 
versus the therapeutic strategy. Even though that all therapies received a substan-
tial SMR, most also had some insufficient ratings with respect to monotherapy. All 
therapies received an ASMR rating of V (no added benefit). In Germany the G-BA 
evaluated seven drugs. Six therapies received a non-added benefit. Albiglutide 
was the only therapy receiving an added benefit (non-quantifiable benefit). All 
comparators were against other active diabetes drugs. One exception was the 
assessment of canagliflozin in combination with metformin which was not only 
compared against drugs but against therapeutic strategies. cOnclusiOns: Using 
the Prismaccess database the analysis shows that there are key differences in 
the assessment of the same clinical data in T2D. In Germany only one therapy 
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Objectives: The purpose of this study was to assess the magnitude of hypoglycemia 
barrier in terms of physician’s treatment choices and algorithm and the impact of 
hypoglycemia in adherence and persistence to insulin treatment. MethOds: Four 
hundred thirteen Turkish physicians were interviewed by close ended questions 
with a mix of dichotomous or bounded continuous response formats. Questions 
were asked face to face in 2 national diabetes congresses, with a physician mix of 
75% internists, 23% endocrinologists, 1,9% family physicians and rest pediatricians 
and obstetrics. Results: Within 413 replies on how important is the hypoglyce-
mia barrier to reach the target HbA1c on an importance scale, 95% replied either 
important or very important. 82% of physicians declared that they would change 
their target HbA1c, if they were not concerned about hypoglycemia. Similarly, 88% 
of physicians believed more of insulin-treated patients might reach target HbA1c 
if physicians are not concerned about hypoglycemia. Among the physicians replied 
79% stated that less than 40% of their patients reported their hypoglycemic status. 
If patients experience hypoglycemia, 75% of physicians would reduce the insulin 
dose for more than 60% of patients, 85% would stop insulin treatment for less than 
20% of patients, 91% would switch to other insulins and 62% would to prefer to keep 
same treatment for less than 20% of the patients. Among the physicians replied, 
35% of them declared that patients are willing to stop treatment due to hypoglyce-
mia and more than 50% declared that patient needs a new insulin that causes less 
hypoglycemia. cOnclusiOns: In this study, physician dimension of hypoglycemia 
was explored. From the results obtained, it is obvious for the Turkish physicians 
that hypoglycemia is perceived as a major barrier for the better treatment of the 
patients. These results show that new treatment options causing less hypoglycemia 
are needed in the treatment of diabetes mellitus.
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Objectives: The rational treatment of all diseases, but especially a chronic disease 
that have common systemic effects, medium and long-term complications such as 
diabetes is extremely important. The aim of the study is to understand medicine 
utilization in type II diabetes in Turkey. MethOds: In order to examine this topic, 
the volume and costs of anti-diabetics, preference rates of the active substances, 
first prescription behavior of physicians were taken from data base (MEDULA) of 
Social Security Institution, the government based reimbursement agency of Turkey 
from year 2007-2014. Descriptive analysis was conducted. Results: Consumption 
of diabetic medicines rose from 638 million TL to 1.116 million TL between 2007 and 
2013, respectively. The majority of the increase came from insulin and analogs that 
rose from 254 million TL to 664 million TL between 2007 to and 2013, respectively. 
84,17% of naïve diabetic patients had been started with anti(?) diabetic protocols 
without insulin in 2013. In additional, metformin was used as 76,24% of all patients 
in 2013 among them. 65,4% of diabetic patients diagnosed between 40-64 age in 2013. 
Approximately 70% of all patients were diagnosed by internal physicians in 2013, 
that ratio seems grooving in recent years. cOnclusiOns: Diabetic medicines are 
one of the mostly consuming medicines in Turkey. In additional, the consumption of 
diabetic medicines was is rising each every year. Diabetic protocols without insulin 
or including metformin have the highest percentage of all treatment protocols. 
Patients were diagnosed with internal physicians while it was expected as family 
physicians depending on clinical guidelines. The analysis may be a guide for poli-
cymakers to understand how the diabetes is managing in Turkey.
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Objectives: Insulin degludec (IDeg) is a long acting basal insulin analogue used 
once-daily in patients with Type 1 and Type 2 diabetes and was approved for use 
in Europe in 2013. A survey among clinicians was conducted to understand the 
initial real world experience from prescribing IDeg. MethOds: Clinicians with 
experience of prescribing IDeg in Germany, Sweden, Luxembourg, Switzerland 
and United Kingdom were invited to answer a short questionnaire in four waves. 
Collected data reflected the type of patients using IDeg, and the realised benefits 
of treatment including reductions in insulin dosing. Patients were not identifi-
able, and responses were anonymised, and qualitative or quantitative analyses 
used where appropriate. Results: In total, 226 clinicians (n) representing 3,083 
patients (pts) responded. In Germany (n= 201), clinicians reported a slight prefer-
ence to use IDeg for patients with T2DM versus patients with T1DM (34.5% versus 
25.5% respectively, with 35.5% stating T1DM and T2DM). Overall, reported clinical 
benefits included improvement in blood glucose control (n= 93, pts= 1440), flex-
ibility for patients (n= 69; pts= 1072) and reduced risk of hypoglycaemia (n= 55, 
pts= 939). Switching to IDeg allowed dose reductions in most patients (44% (n= 100) 
of clinicians representing 55% (n= 1690) of patients). Overall, 74% of clinicians 
(n= 168; pts= 1,856) reported the flexible dosing schedule had a positive impact on 
patients. cOnclusiOns: These early findings in Germany and other European 
countries confirm the results from IDeg randomised clinical trials and indicate real 
world experience with IDeg is positive for both clinicians and patients by adding 
valuable treatment benefits.
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in Malaysia. Undiagnosed and failure to achieve trio Hs treatment goals further 
increased complication and severity of the chronic conditions. Hyperlipidemia 
was highly underdiagnosed and efforts are needed to manage these conditions 
in holistic manner rather than isolation.
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Objectives: For patients with T2DM does telemedicine, compared with standard 
care, provide equivalent clinical outcomes? MethOds: Forty patients with type 2 
diabetes mellitus allocated from October 2011 until July 2012 randomized to either 
treatment at home by video conferences only or the standard outpatient treatment. 
Primary outcomes were HbA1c and blood glucose levels and secondary outcomes 
were 24-h blood pressure, cholesterol levels, and albuminuria. The videotelephone 
was installed and serviced by the telephone company, TDC, Denmark, as a broadband 
solution. Results: The improvements in the two treatments, given as changes in 
percent of telemedicine vs. standard, showed significant differences in HbA1c (-15 
vs. -11 %), mean blood glucose (-18 vs. -13 %,.and in cholesterol (-7 vs. -6 %). No dif-
ferences in LDL (-4 vs. -6 %), weight (-1 vs. 2 %), diastolic diurnal blood pressure (-1 
vs. -7 %), and systolic diurnal blood pressure (0 vs. -1 %) were found. Nine consulta-
tions were missed in the standard outpatient group and none in the telemedicine 
group. cOnclusiOns: The direct comparison of home video consultations versus 
standard outpatient treatment in T2DM, telemedicine was a safe and superior option 
in treatment of T2DM with equivalent or better outcome after six months treatment.
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Objectives: Diabetic foot ulcer (DFU) is the most serious and disabling long term 
complication of diabetes, adversely affecting the health related quality of life 
(HRQoL). This study evaluates the impact of patient-education on HRQoL of DFU 
patients. MethOds: This open-labeled randomized controlled study on the effect 
of patient-education on improvement of HRQoL, conducted in Kasturba Medical 
College Hospital, Manipal, (coastal South India), consisted of 120 DFU patients with 
60 subjects each in the control group [CG] and intervention group [IG]. RAND-36 
questionnaire was employed for evaluating HRQoL scores of DFU patients in both 
groups at baseline and after six months of educational intervention. Results: 
Subjects in the both IG and CG reported poor HRQoL scores, (similar in each group) 
on all the eight subscales at baseline. But, after six months of educational interven-
tion, HRQoL improved substantially in IG with respect to CG as well as IG at baseline 
(p< 0.05). Likewise, in both CG and IG, the physical component summary scale (PCS) 
scores (22.9±6.4 vs 24.4± 7.6) and the mental component summary scale (MCS) 
scores (26.1±5.2 vs 27.6±7.3) were similar and poor before educational intervention. 
However, six months post educational intervention, in IG, the Both PCS and MCS 
scores increased dramatically from 24.4± 7.6 to 41.8±8.6 and 27.6±7.3 to 47.6±5.6 
(p< 0.05) respectively. cOnclusiOns: The remarkable improvement in the HRQoL 
in IG at six months follow-up suggests that patient-education significantly improves 
HRQoL in DFU patients. Overworked physicians and paucity of trained doctors in 
resource-poor settings obligate task-shifting to non-physician healthcare providers. 
Educational intervention is an economical and feasible strategy, especially in the 
context of the ever-increasing burden of non-communicable disease in resource-
poor developing world.
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Objectives: To give knowledge about diabetes and health, to prevent from diabetes 
employees at Health clinic at Songino khairkhan district. MethOds: Survey card 
with 12 questions has been given to 50 professionals, staff and employees which 
was randomly chosen, agreed to fill out survey and who has never been diagnosed 
with diabetes and working in a shift of health clinic. Blood glucose determination 
and body mass index tools are defined by medical instruments and apparatus. 
Survey was carried out from April, 2014 to July, 2014. Research data and results were 
developed by using the software “SPSS -11.5”. Results: 9 employees (38%) were 
30-39 years of age with an average age of 38.6 ± 9, and 44 of them were (88%) female 
and 24 of them were (48%), non-medical professionals, and 32 of them have never 
been done blood sugar test (64%). DISCUSSION: Our research result was related 
with people’s living condition who uses high calorie food because diabetes research 
of Fukashima, M. &Ogowa, K. (2008) have determined that people in the big cities 
uses high calorie foods, and rich carbohydrates food and have physical inactivity 
comparing with people who are living in the countryside. CONCLUSION: The aver-
age age of respondents were 38.6 ± 9, and 15 of them were 40-49 years old.(30%) 32 
of the employees have never given glucose test before (64%) and 15 of them had 
(30%) glucose monitored with 7.6. And 20 of them had heavy weight (40%), and 26 
of them worked for 24 hours (52%).
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